Jul 29, 2026 · 26 min · 10 segments
In this episode Editor-in-Chief Dr. Sadis Matalon (University of Alabama Birmingham) interviews author Dr. Sophia N. Karagiannis (King’s College London) about the recently published Review article by…
Sophia KaragiannisGuest
Sadis MatalonHostCara KehanHost
It is my great pleasure and honor to have served as editor-in-chief of Physiological Reviews for nine years.
And with an impact factor of close to 36, we are one of the top 50 journals in the world.
And I cannot thank enough Cara and Ileana for all their help in making this journal such a great place to publish.
Sophia, many, many thanks to you and your co-authors for this very interesting, highly impactful article, which really promises to be a bestseller.
I would like to start by highlighting just a few of the many accomplishments from your great career.
Dr. Sophia Karagiannis is professor of translational cancer immunology and immunotherapy in the St. John's Institute of Dermatology School of Basic and Medical Bioscience at King's College, London, England.
She leads the antibody discovery and immunotherapy group focused on dissecting the crosstalk between patient immune cells and cancer, and on the design of novel agents for solid tumors such as melanoma, ovarian, and breast cancer.
She was appointed head of cancer antibody discovery and immunotherapy in 2012 at King's College.
Professor Karajanis is also the founder of Epsilon Gen Limited, the first immuno-oncology company dedicated to develop IgE therapeutic agents for cancer.
Professor Karajanis, in your fascinating review article, you refer to antibody drug conjugates as magic bullets, which may kill cancer cells with minimum damage to healthy tissues.
When I was growing up in Greece, having cancer was equivalent to dying within a few years.
Please tell us how ADCs are manufactured to target and kill cancer cells while avoiding healthy cells and organs.
It is my great pleasure and honor to have served as editor-in-chief of Physiological Reviews for nine years.
And with an impact factor of close to 36, we are one of the top 50 journals in the world.
And I cannot thank enough Cara and Ileana for all their help in making this journal such a great place to publish.
Sophia, many, many thanks to you and your co-authors for this very interesting, highly impactful article, which really promises to be a bestseller.
I would like to start by highlighting just a few of the many accomplishments from your great career.
Dr. Sophia Karagiannis is professor of translational cancer immunology and immunotherapy in the St. John's Institute of Dermatology School of Basic and Medical Bioscience at King's College, London, England.
She leads the antibody discovery and immunotherapy group focused on dissecting the crosstalk between patient immune cells and cancer, and on the design of novel agents for solid tumors such as melanoma, ovarian, and breast cancer.
She was appointed head of cancer antibody discovery and immunotherapy in 2012 at King's College.
Professor Karajanis is also the founder of Epsilon Gen Limited, the first immuno-oncology company dedicated to develop IgE therapeutic agents for cancer.
Professor Karajanis, in your fascinating review article, you refer to antibody drug conjugates as magic bullets, which may kill cancer cells with minimum damage to healthy tissues.
When I was growing up in Greece, having cancer was equivalent to dying within a few years.
Please tell us how ADCs are manufactured to target and kill cancer cells while avoiding healthy cells and organs.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.